Press Releases June 4, 2026 07:00 AM

Option Care Health Appoints Robert Okunski as Vice President, Investor Relations

Option Care Health appoints Robert Okunski as Vice President of Investor Relations to enhance investor communication and engagement.

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
OPCH

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, announced the appointment of Robert Okunski as Vice President of Investor Relations. Okunski brings over 20 years of expertise in investor relations across healthcare and technology sectors and will lead the company's strategy to improve communication with the investment community and support its growth strategy.

Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
OPCH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Robert Okunski appointed as Vice President of Investor Relations effective May 26, 2026.
  • Okunski has extensive experience in investor relations across healthcare, technology, and energy sectors.
  • The role focuses on driving investor relations strategy, improving engagement, transparency, and corporate visibility.

BANNOCKBURN, Ill., June 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced the appointment of Robert Okunski as Vice President, Investor Relations effective May 26, 2026.

In this role, Okunski will lead the Company’s investor relations strategy and serve as the primary liaison between Option Care Health and the investment community. He will be responsible for communicating the Company’s business strategy, financial performance, capital allocation priorities and long-term growth opportunities to investors, analysts and other key stakeholders.

“Bob brings more than two decades of investor relations leadership experience across healthcare, technology and energy industries,” said Meenal Sethna, Chief Financial Officer of Option Care Health. “His proven track record of building best-in-class investor relations programs, strengthening investor engagement and enhancing transparency, elevating corporate visibility, will be invaluable as we continue to execute our growth strategy and create long-term shareholder value.”

Okunski joins Option Care Health from Enhabit Home Health & Hospice, where he served as Vice President of Investor Relations. During his tenure, he led the company’s investor relations strategy, enhanced engagement with institutional investors and analysts, and increased the company’s visibility within the investment community.

Prior to Enhabit, Okunski held senior investor relations leadership positions at Velo3D Inc., SunPower Corporation, Spansion Inc. and PeopleSoft.

Okunski holds a Master of Business Administration from Moravian University and a Bachelor of Arts from Colgate University.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.

For Investor Inquiries:

Bob OkunskiVice President, Investor Relationsrobert.okunski@optioncare.com

Risks

  • The effectiveness of the new investor relations leadership in enhancing market perception remains uncertain.
  • Changing investor relations strategy might not immediately translate into tangible stock performance improvements.
  • Broader market or sector-specific conditions could overshadow benefits from enhanced investor outreach.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026